SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-443037"
 

Search: onr:"swepub:oai:DiVA.org:uu-443037" > Detailed Long-Term ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials : MCL2 and MCL3

Eskelund, Christian Winther (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.;Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark.;Univ Copenhagen, Danish Stem Cell Ctr Danstem, Copenhagen, Denmark.
Dimopoulos, Kostas (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.;Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark.;Univ Copenhagen, Danish Stem Cell Ctr Danstem, Copenhagen, Denmark.
Kolstad, Arne (author)
Oslo Univ Hosp, Dept Oncol, Oslo, Norway.
show more...
Glimelius, Ingrid, 1975- (author)
Karolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi
Raty, Riikka (author)
Helsinki Univ Hosp, Dept Haematol, Helsinki, Finland.
Gjerdrum, Lise Mette Rahbek (author)
Zealand Univ Hosp, Dept Pathol, Roskilde, Denmark.;Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
Sonnevi, Kristina (author)
Karolinska Institutet,Karolinska Univ Hosp, Dept Haematol, Stockholm, Sweden.
Josefsson, Par (author)
Herlev Hosp, Dept Haematol, Herlev, Denmark.
Nilsson-Ehle, Herman (author)
Sahlgrens Univ Hosp, Dept Haematol, Gothenburg, Sweden.
Bentzen, Hans H. N. (author)
Aarhus Univ Hosp, Dept Haematol, Aarhus, Denmark.
Fagerli, Unn Merete (author)
St Olavs Hosp, Dept Oncol, Trondheim, Norway.;Norwegian Univ Sci & Technol NTNTU, Inst Clin & Mol Med IKOM, Trondheim, Norway.
Kuittinen, Outi (author)
Kuopio Univ Hosp, Dept Oncol, Kuopio, Finland.
Haaber, Jacob (author)
Odense Univ Hosp, Dept Haematol, Odense, Denmark.
Niemann, Carsten Utoft (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.
Pedersen, Lone Bredo (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.
Larsen, Maria Torp (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.
Geisler, Christian Hartmann (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.
Hutchings, Martin (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.
Jerkeman, Mats (author)
Skane Univ Hosp, Dept Oncol, Lund, Sweden.
Gronbaek, Kirsten (author)
Rigshosp, Dept Haematol, Copenhagen, Denmark.;Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark.;Univ Copenhagen, Danish Stem Cell Ctr Danstem, Copenhagen, Denmark.
Grønbæk, K (author)
show less...
Rigshosp, Dept Haematol, Copenhagen, Denmark;Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark.;Univ Copenhagen, Danish Stem Cell Ctr Danstem, Copenhagen, Denmark. Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (creator_code:org_t)
Wolters Kluwer, 2021
2021
English.
In: HemaSphere. - : Wolters Kluwer. - 2572-9241. ; 5:1
Related links:
https://doi.org/10.1...
show more...
https://uu.diva-port... (primary) (Raw object)
https://urn.kb.se/re...
https://doi.org/10.1...
http://kipublication...
http://kipublication...
show less...
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The prognosis after relapse is generally poor, and no standard of care exists. We investigated the postrelapse outcomes of 149 patients who were initially treated in the Nordic Lymphoma Group trials, MCL2 or MCL3, both representing intensive cytarabine-containing frontline regimens including autologous stem cell transplant. Patients with progression of disease before 24 months (POD24, n = 51, 34%) displayed a median overall survival of 6.6 months compared with 46 months for patients with later POD (n = 98, 66%; P < 0.001). MCL international prognostic index, cell proliferation marker, blastoid morphology, and TP53 mutations showed independent prognostic value irrespective of POD24, and in a combined, exploratory risk score, patients with 0, 1, 2-3, or 4-5 high-risk markers, respectively, displayed a 5-year overall survival of 62%, 39%, 31%, and 0%. By a comparison of median progression-free survival of the different salvage therapies in the relapse setting, bendamustine-rituximab was superior to all other combination chemotherapy regimens; however, it was also associated with longer responses to last line of therapy. Collectively, we confirm the prognostic impact of POD24 and highlight the relevance of other biomarkers, and we emphasize the importance of novel therapies for patients with high-risk features at first POD.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • HemaSphere (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view